 |
|
|
| |
A Randomized, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Graham R. Foster1, Alexander Thompson2, Peter J. Ruane3, Sergio Borgia4, Gregory Dore5, Kimberly Workowski6, Robert H. Hyland7, Jing Wang7, Evguenia S. Svarovskaia7, Luisa M. Stamm7, Diana M. Brainard,
G. Mani Subramanian, John G. McHutchison7, Thomas Berg8, Kosh Agarwal9, Brian Conway10, Jordan Feld11, Bernard Willems12, Stuart K. Roberts13
1 Royal London Hospital, London, UK; 2 St. Vincent's Hospital, Department of Gastroenterology, Melbourne, Victoria, Australia; 3 Ruane Medical and Liver Health Institute, Los Angeles, CA; 4 William Osler Health System, Brampton Civic Hospital, Ontario, Canada, 5 St. Vincent's Public Hospital, Sydney, New South Wales, Australia; 6 Emory University, Atlanta, GA; 7 Gilead Sciences, Inc., Foster City, CA; 8 Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Germany; 9 Institute of Liver Studies, Kings College Hospital, London, UK; 10 Vancouver Infectious Disease Research and Care Centre, British Columbia, Canada; 11 Toronto Western Hospital Liver Centre, Ontario, CA; 12 Centre Hospitalier de l'Université de Montréal, Québec, Canada; 13 Alfred Hospital, Melbourne, Victoria, Australia
|
| |
|
|
|
|
|
